PubMed ID:
11565518
Public Release Type:
Journal
Publication Year: 2001
Affiliation: Renal Division, Brigham and Women's Hospital, Boston, MA 02115, USA. bbrenner@partners.org
DOI:
https://doi.org/10.1056/NEJMoa011161
Authors:
Remuzzi G,
Brenner BM,
Cooper ME,
de Zeeuw D,
Keane WF,
Mitch WE,
Parving HH,
RENAAL Study Investigators,
Shahinfar S,
Snapinn SM,
Zhang Z
Studies:
Chronic Renal Insufficiency Cohort Study
Diabetic nephropathy is the leading cause of end-stage renal disease. Interruption of the renin-angiotensin system slows the progression of renal disease in patients with type 1 diabetes, but similar data are not available for patients with type 2, the most common form of diabetes. We assessed the role of the angiotensin-II-receptor antagonist losartan in patients with type 2 diabetes and nephropathy.